Loading company…
Nutcracker Therapeutics develops RNA medicines using an integrated design, delivery, and manufacturing platform.
Founded in 2018, Nutcracker Therapeutics combines RNA design, nanoparticle delivery, and GMP biochip-based manufacturing to develop RNA treatments for complex diseases. It serves clinical investigators and medical institutions. The company is based in Emeryville, US, and is at Series C stage; in August 2021, it raised USD 144.50 mn led by ARCH Venture Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in